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Abstract
Matrix metalloproteinase (MMP) 13 (collagenase 3) is an extracellular matrix remodeling enzyme that is induced in
myofibroblasts during the earliest invasive stages of human breast carcinoma, suggesting that it is involved in tumor
progression. During progression of mammary carcinomas in the polyoma virus middle T oncogene mouse model (MMTV-
PyMT), Mmp13 mRNA was strongly upregulated concurrently with the transition to invasive and metastatic carcinomas. As in
human tumors,Mmp13mRNAwas found in myofibroblasts of invasive grade II and III carcinomas, but not in benign grade I and
II mammary intraepithelial neoplasias. To determine if MMP13 plays a role in tumor progression, we crossed MMTV-PyMT mice
with Mmp13 deficient mice. The absence of MMP13 did not influence tumor growth, vascularization, progression to more
advanced tumor stages, or metastasis to the lungs, and the absence of MMP13 was not compensated for by expression of other
MMPs or tissue inhibitor of metalloproteinases. However, an increased fraction of thin collagen fibrils was identified in MMTV-
PyMT;Mmp132/2 compared toMMTV-PyMT;Mmp13+/+ tumors, showing that collagen metabolism was altered in the absence of
MMP13. We conclude that the expression pattern ofMmp13mRNA inmyofibroblasts of invasive carcinomas in the MMTV-PyMT
breast cancer model recapitulates the expression pattern observed in human breast cancer. Our results suggest that MMP13 is a
marker of carcinoma-associated myofibroblasts of invasive carcinoma, even though it does not make a major contribution to
tumor progression in the MMTV-PyMT breast cancer model.
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Introduction
The ability of cancer cells to invade or metastasize to distant
organs is linked to their ability to traverse the extracellular matrix.
The extracellular matrix (ECM) is a heterogeneous protein matrix
that consists of a variety of collagens, laminins, fibronectin and
proteoglycans [1,2]. Matrix metalloproteinases (MMP) cleave and
remodel ECM components [3], and increased activity of some of
the MMPs, including MMP2, 9, and 14 can promote cancer cell
invasion in vivo [3–7].
MMP13 (collagenase-3) was originally identified in human breast
cancer tissue [8]. It is secreted from cells as an inactive zymogen that
can be activated by the MMP2/MMP14/tissue inhibitor of
metalloproteinase (TIMP2) complex [9] or by plasmin [10].
MMP13 acts in the extracellular environment as a potent
collagenase capable of degrading a variety of collagens [11].
Mmp13 mRNA is expressed in a subpopulation of myofibroblasts
in invasive ductal breast carcinomas [12], but rarely in normal
breast, benign breast lesions and ductal carcinoma in situ (DCIS).
Interestingly, the presence of microinvasion in DCIS is associated
with focal expression of Mmp13 mRNA in stromal fibroblasts
[12,13]. Direct comparison of the Mmp13 mRNA expression pattern
with that of the Mmp2, Mmp11 and Mmp14 mRNAs indicates that
Mmp13 is unique in this respect since these other MMPs are also
present in DCIS in the absence of invasion [12]. These observations
raise the question as to whether MMP13 is a rate-limiting proteinase
that mediates the initial steps in breast cancer invasion.
The role of MMPs and other ECM-degrading proteinases
during breast cancer progression has been studied using a variety
of murine mammary tumor models [6]. In one model, tumors are
induced by expressing the polyoma middle T oncogene under the
mouse mammary tumor virus LTR (MMTV-PyMT) [14] leading
to early onset hyperplasia in the mammary glands [15]. The
PyMT-oncogene induced mammary tumors go through typical
pre-invasive, invasive and metastatic phases similarly to human
breast cancer [14]. The onset of tumorigenesis in the MMTV-
PyMT mouse model is observed at 2–3 weeks after birth, and the
non-invasive early stage tumors, mammary intraepithelial neopla-
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sia (MIN), progress into invasive carcinomas at 7–9 weeks after
birth [15,16]. Transition to invasive carcinoma takes place in the
central core of the tumors, where epithelial atypia and nuclear
pleomorphism first appear [15]. Tumors isolated from 13-week-old
mice, late stage tumors, show evidence of dedifferentiation and
squamous metaplasia and have spread to the lungs and lymph nodes
[14,15]. The tumors share both morphological and molecular
characteristics with human invasive ductal carcinomas [14,15,17–
19]. Furthermore, we have reported that Mmp2, 3, 11, 13 and 14
mRNAs are expressed in the stromal compartment in a series of late
stage MMTV-PyMT tumors, similar to the expression in human
ductal breast cancers [18]. In late stage tumors, Mmp13 mRNA
shows high, focal expression in stromal cell populations [20]. Since
this expression pattern is similar to what we have observed in human
breast cancers [12], we chose the MMTV-PyMT mouse breast
tumor model to test the functional role of MMP13 in breast cancer
progression and metastasis.
Materials and Methods
Mice
MMTV-PyMT and Mmp132/2 mice have previously been
described [14,21]. Both strains were backcrossed more than 8
generations to FVB/n. The two strains were intercrossed and the
resulting MMTV-PyMT;Mmp13+/2 male offspring were mated with
female Mmp13+/2 mice to establish sibling cohorts of MMTV-
PyMT;Mmp13+/+ and MMTV-PyMT;Mmp132/2 females. All animal
experiments were conducted according to institutional guidelines
and approved by the Danish Animal Experiments Inspectorate. A
concurrent health report compliant with the guidelines of the
Federation of European Laboratory Animal Science Associations
revealed no infections.
Genotyping
Genotyping was performed on chromosomal DNA purified
from tail tips [22] in a single PCR reaction using MMTV-PyMT
primers, control wt plasminogen primers [23] and Mmp13 primers
(MMP13_in5 anti: GGT GGT ATG AAC AAG TTT TCT GAG
C, MMP13_in2: CAG ACC CTA CAG TGC CAG ATT TTA
G, MMP13_ex5: TGA TGA CGT TCA AGG AAT TCA GTT
T). Bands representing MMTV-PyMT transgene (159 bp),
plasminogen (268 bp), wt Mmp13 (572 bp) and Mmp13 knock-out
allele (672 bp) were identified by agarose gel electrophoresis.
Quantitative real time PCR
Mice were anesthetized by intraperitoneal administration of a
1:1 mixture of Dormicum (Roche A/S, Basel, Switzerland) and
Hypnorm (Janssen-Cilag Ltd, High Wycombe, UK) and sacrificed
by intracardial perfusion with 10 ml ice-cold phosphate-buffered
saline (PBS). For analysis of Mmp13 mRNA expression during
normal mammary gland development and MMTV-PyMT
tumorigenesis, the #4 mammary glands were isolated from
MMTV-PyMT mice and wild type FVB/n mice at 3, 5, 7, 9,
11 and 13 weeks (n = 5 for each age and genotype). For analyses of
the expression of other MMPs and TIMPs, tumors from 11-week
old MMTV-PyMT;Mmp13+/+ (n = 6) and MMTV-PyMT;Mmp132/
2 mice were used (n = 6). Total mRNA was isolated from 100 mg
tissue using the Qiagen RNeasy midi Kit (Qiagen, West Sussex,
UK). The purified RNA samples were treated with DNase I for
15 minutes at 37uC to remove residual DNA. Reverse transcrip-
tion was performed essentially as described [24] followed by
TaqMan qPCR performed as described [25] using an ABI7900
(Applied Biosystems, Foster City, CA) and primers specified in
[26] except that Mmp13 primers were chosen from the universal
probe library (number 105, Roche Applied Science, Burgess Hill,
UK), left: CTT TTC CTC CTG GAC CAA ACT, right: TCA
TGG GCA GCA ACA ATA AA. Gene expression levels relative
to 18S were calculated.
In situ hybridization
13-week-old mice were anesthetized as above and perfused
intracardially with 10 mL PBS followed by 10 mL of 4%
paraformaldehyde (PFA). Mammary tumors were dissected from
glands #1–3 and #4, fixed in 4% formalin for 5–7 days at 4uC
and paraffin embedded. In situ hybridization was performed on
samples from MMTV-PyMT;Mmp13+/+ mice (n = 10) with 35S
labeled RNA probes for MMP13 as described previously [27]. No
Mmp13 mRNA signal was detected in tumors from MMTV-
PyMT;Mmp132/2 mice (n = 4).
Immunohistochemistry
For immunohistochemical staining of a-smooth muscle-actin
(mouse mAb, Dako, Glostrup, Denmark) and CD204 (rat mAb clone
2F8, Serotec, Oxford, UK), sections were heat-treated at 98uC in
TEG buffer (10 mmol/L Tris, 0.5 mmol/L EGTA, pH 9.0) for
5 minutes in a T/T Micromed microwave processor (Milestone,
Sorisol, Italy). The a-smooth muscle-actin antibody was mixed with
biotinylated anti-mouse Fab fragments using the Animal Research
Kit (Dako) and used for staining following the recommendations of
the manufacturer. The rat mAb against CD204 was detected with
rabbit anti-rat antibodies followed by Envision-Rabbit reagent
(Dako). All antibody incubation steps were performed in an
OptiMax automated immunostainer (BioGenex, San Ramon, CA).
Immunohistochemical staining combined with in situ hybridization
was performed on mouse glands#1–3 tumor samples from MMTV-
PyMT;Mmp13+/+ mice (n = 6) as described previously [12]. The
sections were developed with DAB chromogene, fixed for 40 min-
utes in 4% PFA, and washed three times with sterile water. After
dehydration, the sections were incubated with 35S-labeled Mmp13
antisense probes and further treated according to the in situ
hybridization as described previously [27].
Morphometric analysis of mammary gland whole mounts
The #4 mammary glands were isolated from 4- and 6-week-old
MMTV-PyMT;Mmp13+/+ mice (n = 4 and n = 4, respectively) and
MMTV-PyMT;Mmp132/2 mice (n = 3 and n = 7, respectively) and
prepared for whole mount as described [28]. The whole mounts
were photographed using a DFC320 CCD camera (Leica
Microsystems, Wetzlar, Germany) and the ductal epithelial
invasion determined by measuring the distance from the branch
point closest to the nipple to the three most far-reaching ducts and
the edge of the fat pad. The penetration is presented as the mean
of the three measures of ductal penetration related to the length to
the edge of the fat pad. All measurements were done using the
Leica IM500 software.
Tumor growth and lung metastasis
Tumor growth in MMTV-PyMT;Mmp13+/+ mice (n = 38) and
MMTV-PyMT;Mmp132/2 mice (n = 25) was followed by weekly
palpations of all 10 mammary glands. The length and width of all
palpable tumors were measured by caliper. The tumor volume
(assuming that tumors took the shape of an ellipsoid) was
calculated using the formula: V= (p/6)6W26L, where L= length
and W= width. At 13 weeks, MMTV-PyMT;Mmp13+/+ mice
(n = 35) and MMTV-PyMT;Mmp132/2 mice (n = 25) were anes-
thetized and perfusion fixed (three mice had been terminated
before due to extensive tumor burden). The lungs were removed
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for determination of the metastasis burden by stereological analysis
using Cavalieri’s principle as described previously [29].
Tumor grading
Nuclear grading of the MMTV-PyMT tumors was performed
on haematoxylin and eosin (H&E) stained sections from the #1–3
tumors of MMTV-PyMT;Mmp13+/+ mice (n = 34) and MMTV-
PyMT;Mmp132/2 mice (n = 24). We defined grade I tumors as
tumors with adenoma and atypia in Mammary Intraepithelial
Neoplasia (MIN)-like foci and containing up to 5% of MIN with
grade II nuclear pleiomorphy. Grade II tumors (‘‘Early carcino-
ma’’ [15]) were tumors with widespread invasive carcinoma with
grade II nuclear pleiomorphy and contained areas with MIN
Grade I/II. Grade III tumors (‘‘Late carcinoma’’) were tumors
with focal or widespread invasive carcinoma with grade III nuclear
pleiomorphy that also contained areas with Grade I and II
carcinoma. Most tumors with grade III carcinoma showed areas of
squamous metaplasia.
Quantification of angiogenesis
Mice were anesthetized as above and 100 mL of 1 mg/mL
FITC-conjugated Lycopersicon esculentum (tomato) lectin (Vector labs)
injected i.v. in the tail vein. After 5 min, the mice were cardiac
perfused with 4% PFA in PBS at 120–140 mm Hg until the flow-
through fluid was clear. Tumors were dissected and post-fixed in
4% PFA overnight, incubated in increasing sucrose concentrations
(12%, 15%, 18% in PBS), embedded in Tissue-Tek O.C.T.
compound and thick sections (30–40 mm) cut. The tissue sections
were stained with 1:500 solution of Propidium Iodide in PBS
(Molecular probes, P-3566) for 1 hour and the slides were
mounted with Gel/Mount (Biomeda, #M01). Confocal image
stacks with 1-mm spacing were collected from the most
vascularized area in the middle of the tumors using a 20x lens
with a Solamere micro-lensed spinning disk confocal microscope
(Solamere Technologies, Salt Lake City UT) equipped with an
intensified charge-coupled device (ICCD) camera (XRMega-
10EX S-30, Stanford Photonics, Palo Alto, CA). The acquired
images were analyzed with Bitplane Imaris version 5.5 for
Windows software using ‘filament tracer’ with an approximate
filament diameter set at 1.5. Minor manual corrections of the
computerized filaments were uniformly done. Vessel (segment)
average diameter, length and volume, were exported to a
Microsoft Excel file and analyzed using GraphPad 4 statistical
software. Eight tumors from MMTV-PyMT;Mmp13+/+ and nine
tumor from MMTV-PyMT;Mmp132/2 were analyzed. All image
acquisition and analysis was done blindly.
Cell proliferation analysis
MMTV-PyMT;Mmp13+/+ mice (n = 19) and MMTV-
PyMT;Mmp132/2 mice (n = 19) were injected i.p. with 2 mg
bromodeoxyuridine (BrdU, Sigma-Aldrich) 2 hours before eutha-
nasia. The mice were anesthetized, perfusion fixed, the tumors
isolated and fixed in 4% PFA and finally paraffin embedded as
described above. For immunohistochemistry, we used a rat mAb
against BrdU at 2 mg/mL (clone BU1/75-ICR1, Abcam, Cam-
bridge, UK). The BrdU labeled cells were counted as a percentage
of the total number of epithelial tumor cells using CastGRID
(Visiopharm, Hørsholm, Denmark) essentially as previously
described [30]. In brief, frames of 9391 mm2 were systematically
but randomly placed over the BrdU stained sections with a final
magnification of 658 on the monitor. All BrdU positive neoplastic
cells within the frames were counted to give total numbers varying
from 250–400. The total number of neoplastic cells within the
frames was estimated based on the usage of systematic and
randomly positioned reference points [30].
Collagen evaluation
Serial sections (3-mm thick) from mammary tumor glands #1–3
obtained from 13-week-old MMTV-PyMT;Mmp13+/+ mice (n = 26)
and MMTV-PyMT;Mmp132/2 mice (n = 21) were stained with
haematoxylin and eosin (H&E) or picrosirius red (PSR) [31]. Areas
with invasive tumor were identified in H&E stained sections. The
same areas were then analyzed in the PSR stained sections by
obtaining 2.361.8 mm images with a charge-coupled device
(CCD) camera (Leica) under linearly polarized light using a Leica
DMRBE microscope. In linearly polarized light, thick collagen
bundles appear orange-red and thin collagen fibers green [32].
Images were analyzed with MetaMorph software for collagen
content. Total collagen was identified with Hue-Saturation-
Intensity (HSI) intervals 0–256, 1–256 and 70–256, respectively.
For thin fibrillar collagen, HSI settings of 26–83, 70–135, and 57–
155 were applied to all the images. All image acquisition and
analysis was done blindly. The area covered by total collagen, thin
fibrillar collagen, and the fraction of thin fibrillar collagen was
calculated and used for statistical analysis (t-test).
Statistics
For statistical analyses of the tumor burdens obtained by caliber
measurements, the total tumor volumes were logarithmically
transformed and analyzed using a general linear model with
repeated measures. Only measurements obtained from week 7 to
13 were included in this analysis. Estimates were obtained using
generalized estimating equations (SAS v9.1). Statistical interaction
between genotype and time were evaluated for the entire observation
period considering repeated measures (SAS). For statistical analyses
of the metastasis burdens, the values were logarithmically trans-
formed and analyzed using a general linear model.
Results
Mmp13 is expressed by myofibroblasts in invasive stage
MMTV-PyMT tumors
Mmp13 mRNA is expressed by a subpopulation of myofibro-
blasts in human invasive ductal breast carcinomas, but is rarely
expressed in normal breast, benign breast lesions and ductal
carcinoma in situ (DCIS) [12]. To determine if the expression level
of MMP13 changes during tumor progression in the MMTV-
PyMT mouse model, Mmp13 mRNA levels were assessed in tumor
tissue from mice at 3-13 weeks of age by qPCR. The level of
Mmp13 mRNA was highly increased in MMTV-PyMT tumors
after 7-weeks of age, with the highest levels found in older mice,
corresponding to late stage tumors (Fig. 1). Mmp13 mRNA levels
were low in normal mammary glands at all ages. The increase in
Mmp13 mRNA thus took place during the time of transition to
invasive stages in this tumor model [15].
To determine where Mmp13 was expressed, we performed in situ
hybridization in tumors from 13-week-old mice, containing
different stages of nuclear grading. The Mmp13 mRNA signal
was seen in stromal fibroblast-like cells located in the tumor core in
areas with invasive grade II and III carcinoma (‘‘late carcinoma’’),
but was generally absent in the tumor periphery that was
dominated by normal-looking mammary tissue, hyperplasia or
MIN grade I and II (Fig. 2a–d). In particular, Mmp13 mRNA
positive cells were often seen in stromal branches located close to
the tumor cores with focal necrosis (Fig. 2i). Sporadic Mmp13
mRNA positive single cells and small cell clusters were also found
in areas with strongly keratinized, squamous metaplastic changes
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(Fig. 2j). This focal expression of Mmp13 in the tumor core was
very different from the expression of Mmp2 and Mmp14, which
were found throughout the tumor stroma, including at the tumor
periphery (Fig. 2 e–h), and in areas with hyperplasia, grade I and
grade II MIN (not shown).
The localization of the cells that expressed Mmp13 suggested that
they were myofibroblasts. Using combined in situ hybridization and
immunohistochemical staining, we verified that most of the Mmp13
mRNA positive cells were positive for the myofibroblast marker a-
smooth muscle-actin (Fig. 2k), paralleling the expression we found in
human breast cancers [12]. Myofibroblasts are prevalent in the
invasive MMTV-PyMT tumors, but only a small subpopulation was
positive for Mmp13 mRNA. We noted that some of the Mmp13
mRNA positive myofibroblasts were located in narrow bands
between tumor cell clusters (Fig. 2l). CD204 positive macrophages
did not express Mmp13 mRNA and the location of the Mmp13
mRNA positive cells was not consistent with myoepithelial cells (data
not shown), supporting our conclusion that the stromal Mmp13
mRNA expressing cells were myofibroblasts.
Early tumor formation does not require MMP13 in MMTV-
PyMT
The expression levels and patterns of Mmp13 mRNA suggested
that the proteinase would play a role in the transition to the
invasive stages. To determine the role of MMP13 in mouse
mammary tumor progression, we took a genetic approach using
Mmp132/2 mice. We verified that the absence of MMP13 did not
affect the development of the mammary epithelium (Fig. 3A) and
therefore would not affect tumor progression indirectly by
Figure 1. Expression of Mmp13 mRNA is induced at 7 weeks of
age in MMTV-PyMT tumors. Mmp13 mRNA levels determined by
qPCR during normal development (N) and MMTV-PyMT induced tumor
progression (m) in the #4 mammary gland (n = 661 for each time
point). Values represent mean6standard error of the mean (SEM).
doi:10.1371/journal.pone.0002959.g001
Figure 2. Mmp13 mRNA is expressed by a subset of a-smooth muscle actin positive carcinoma-associated fibroblasts. MMTV-PyMT
tumors from 13-week-old mice were processed for in situ hybridization for Mmp13 (a–e, i–l), Mmp2 (g), and Mmp14 (h). For clarity the hybridization
signals (silver grains) are shown with dark-field illumination in b, d, f, g, and h. (c) and (d) are higher magnification of the area with grade III invasive
carcinoma framed in (a) and (b). Mmp13 mRNA signal is seen in the areas with grade III invasive carcinoma (c–d, arrows), but not in the surrounding
areas with grade I and II MIN (indicated by I and II in a and b). Mmp13 mRNA expression is restricted to the tumor core (f, white arrows), whereas
Mmp2 (g) and Mmp14 (h) mRNAs are seen also in the tumor periphery (blue arrows, f, g, and h are adjacent sections). Stromal septae with Mmp13
mRNA positive signal (i, arrows) are seen in areas close to necrotic tissue (N). Mmp13 mRNA signal in tumor areas with squamous metaplasia showing
keratinized (K) epithelium (j, arrows). Expression of Mmp13 mRNA is seen in a-smooth muscle-actin immunoreactive myofibroblasts (k and l, arrows),
in some areas restricted to myofibroblasts in the delicate strands of stromal tissue within the cellular tumor (l, arrows). All sections were counter-
stained with haematoxylin and eosin except (k and l) that were stained with haematoxylin only. Bars: a, b: 700 mm; c, d: 100 mm; e–i: 400 mm; j:
200 mm; k, l: 50 mm.
doi:10.1371/journal.pone.0002959.g002
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influencing the number of mammary epithelial cells. We next
crossed the MMTV-PyMT mice with Mmp132/2 mice and
measured the total hyperplastic area on whole-mounts of
mammary glands from mice at age 4 or 6 weeks, before the
transition to invasive carcinoma. No difference was found between
MMTV-PyMT;Mmp13+/+ and MMTV-PyMT;Mmp132/2 mice
(Fig. 3B), consistent with the lack of Mmp13 mRNA expression
at the early cancer stage.
MMP13 is not required for tumor growth, tumor
vascularization or metastasis in MMTV-PyMT mammary
carcinomas
Mmp13 mRNA was induced in tumors from mice of 7–9 weeks-of-
age, and we therefore expected that MMP13 would be required in
the later stages of tumorigenesis, possibly affecting tumor growth and
metastasis. We followed tumor growth in a cohort of littermate
MMTV-PyMT;Mmp13+/+ (n = 38) and MMTV-PyMT;Mmp132/2
females (n = 25) by weekly palpations and caliper measurements until
13 weeks of age, when tumors were isolated for histological
examination and the lungs isolated to determine metastasis burden.
A minor reduction in the growth of the tumors in MMTV-
PyMT;Mmp132/2 mice were seen at 8, 9, 11, 12 weeks (Fig. 4A), but
this was not reproduced in a different cohort (Fig. 4B). Furthermore,
there were no differences in cancer cell proliferation between tumors
from MMTV-PyMT;Mmp13+/+ and MMTV-PyMT;Mmp132/2 mice
at 8 or 11 weeks of age as determined by BrdU-labeling (Fig. 5C). In
addition, histological examination and nuclear grading of the tumors
revealed no significant differences in the percentages of tumors that
had progressed to grade III, late-stage carcinoma (Fig. 4C, 8% of the
MMTV-PyMT;Mmp132/2 vs. 18% of MMTV-PyMT;Mmp13+/+
tumors). Furthermore, analyses of H&E stained sections revealed no
differences in the presence of necrosis or stroma between tumors
from MMTV-PyMT;Mmp132/2 and MMTV-PyMT;Mmp13+/+
mice (not shown). Finally, no effects were seen on tumor
vascularization, when analyzing vessel diameter, length, or volume
in 3D reconstructions of vessels in tumors of lectin-perfused mice
(Fig. 5A, B). Thus, the absence of MMP13 did not influence
progression in the primary tumors.
Figure 3. Mammary gland development and early tumor development is not influenced by MMP13. (A) Morphometric analysis of ductal
epithelial penetration during normalmammary gland development. Representative wholemount-stained#4mammary glands fromMmp13+/+ (n= 4 and
n=4 at 4 and 6 weeks of age, respectively), andMmp132/2mice (n=3 and n=7 at 4 and 6weeks of age, respectively. The distances from the nipple to the
threemost far-reaching ducts and to the edge of the fat pad were measured. Themean ductal epithelial penetration as percentage of the whole fat pad is
shown with the SEM. (B)Morphometric analysis of early MMTV-PyMT tumor growth. Representative whole mount-stained#4 gland tumors fromMMTV-
PyMT;Mmp13+/+ and MMTV-PyMT;Mmp132/2 mice at 6-weeks-of-age. The tumor area was measured in 4- and 6-week-old MMTV-PyMT;Mmp13+/+ (n= 5
and n=7, respectively) and MMTV-PyMT;Mmp132/2 mice (n= 3 and n=10, respectively) and are presented as mean with the SEM.
doi:10.1371/journal.pone.0002959.g003
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Since MMP13 is upregulated concomitantly with the onset of
cancer cell dissemination in the MMTV-PyMT model [16], we
determined the metastatic burden in the lungs from end-stage
MMTV-PyMT;Mmp13+/+ and MMTV-PyMT;Mmp132/2 mice using
a morphometric approach [29]. Although there was a trend for a
reduced lung metastatic volume in the absence of MMP13, this was
not significant (Fig. 4D, 1.2 mm3 for MMTV-PyMT;Mmp13+/+,
n = 35; 0.7 mm3 for MMTV-PyMT;Mmp132/2, n = 25, p= 0.34).
We therefore conclude that the absence of MMP13 does not affect
lung metastasis in the MMTV-PyMT breast cancer model.
Figure 4. MMTV-PyMT primary tumor growth and metastasis is not influenced by MMP13. (A) MMTV-PyMT tumor growth determined by
weekly caliber measurements. Total tumor volumes are presented as mean +/2 the SEM. (N)MMTV-PyMT;Mmp13+/+, n = 38, (m)MMTV-PyMT;Mmp132/2,
n = 25 . Three MMTV-PyMT;Mmp13+/+ mice were terminated before the end of the experiment due to extensive tumor burden, one at 8 weeks
and two after 12 weeks. (B) MMTV-PyMT tumor growth determined by weekly caliber measurements in another cohort. (N) MMTV-
PyMT;Mmp13+/+, n = 6, (m) MMTV-PyMT;Mmp132/2, n = 7. The total weight of the tumors at 11 weeks was 1.42g60.22 SEM for the MMTV-
PyMT;Mmp13+/+ mice and 1.44g60.16 SEM for the MMTV-PyMT;Mmp132/2 mice. (C) Nuclear grading of the MMTV-PyMT tumors. Nuclear
grading was performed on representative H&E stained sections from mammary tumors glands #1–3 from 13-week-old MMTV-PyMT;Mmp13+/+
(n = 34) and MMTV-PyMT;Mmp132/2 (n = 24) mice by a pathologist (FR) unaware of the genotypes. Nuclear grading was independent of
genotype. (D) Lung metastasis volumes determined by stereology using Cavalieri’s principle. The total metastasis volume was determined in
lungs obtained from the 13-week-old mice by an observer unaware of the genotypes. Median values are 1.2 mm3 in the MMTV-
PyMT;Mmp13+/+ (n = 35) and 0.7 mm3 (n = 25) in MMTV-PyMT;Mmp132/2 mice, respectively.
doi:10.1371/journal.pone.0002959.g004
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Figure 5. Vascularization of MMTV-PyMT tumors is not affected by MMP13. (A) Maximum intensity projections of confocal image stacks
from tumor sections showing cell nuclei (red, propidium iodide stained) and vasculature (green, with FITC-conjugated lycopersicon esculentum
lectin). (B) No significant differences were observed in vessel diameter (p = 0.95), length (p = 0.4) or volume (p = 0.4) when comparing vessels in
tumors from MMTV-PyMT;Mmp13+/+ (n = 9) and MMTV-PyMT;Mmp132/2mice (n = 9, t-tests). All analyses were done blindly. (C)Morphometric analysis
of the proliferation rate in the MMTV-PyMT tumors. Representative immunohistochemical staining for BrdU in an MMTV-PyMT tumor with counting
frames applied to the tissue sections (left). Tumor cell proliferation was determined by an observer unaware of the genotypes in one#1–3 gland and
one #4 gland tumor from each mouse. MMTV-PyMT;Mmp13+/+, n = 8 and n=11 at 8 and 11 weeks, respectively, MMTV-PyMT;Mmp132/2, n = 7 and
n= 12 at 8 and 11 weeks, respectively (three samples were excluded due to poor morphology). The proliferation rates are shown as the percentage of
the total number of neoplastic cells with medians 50% (box) and 95% inclusion intervals (right).
doi:10.1371/journal.pone.0002959.g005
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There are no compensatory changes in expression of
MMPs or TIMPs in MMTV-PyMT;Mmp132/2 tumors
Since we found no changes in tumor progression in the absence
of MMP13, we explored the possibility that the lack of MMP13
activity was compensated for by changes in expression of other
MMPs or in their inhibitors, the TIMPs. However, there were no
significant differences in the mRNA levels for MMP2, -3, -8, -9, -
10, -11, -12, -13, -14 or TIMP1, -2, -3, or -4 in tumors with and
without MMP13 from 11-week-old mice by qPCR (Fig. 6).
Increased amounts of thin collagen fibers is found in the
absence of MMP13 in invasive areas of MMTV-PyMT
tumors
To determine whether any effects of MMP13 could be seen on its
major substrate, fibrillar collagen, we evaluated the fibrillar collagen
content in invasive areas of the tumors by picrosirius red staining of
tumor sections (Fig. 7A). Although total collagen was not affected by
the absence of MMP13, the fraction of thin collagen fibers relative to
total collagen was increased significantly by ,30% in the invasive
areas of tumors from MMTV-PyMT;Mmp132/2 mice (Fig. 7B, t-
test, p = 0.007). Thus, MMP13 played a role in collagen metabolism
in invasive areas of MMTV-PyMT tumors, but this did not affect
tumor progression.
Discussion
In this study, we analyzed the effects of absence of MMP13
activity on the progression of MMTV-PyMT mammary carcino-
ma. Our previous studies of human DCIS with early invasion led
us to hypothesize that MMP13 would be a fibroblast-derived,
potential rate-limiting proteinase in the transition from non-
invasive to invasive breast carcinoma [12]. Interestingly, a recent
study reported upregulation of several MMPs, including MMP13,
at the transition from non-invasive to invasive breast cancer cells
in an in vitro model [33]. However, although Mmp13 mRNA also
was strongly induced in a subpopulation of myofibroblasts in
MMTV-PyMT mammary carcinomas, concurrent with early
transition to invasive carcinoma, there were no effects on tumor
cell proliferation, tumor growth, lung metastasis, vascularization or
differentiation of the primary tumors by the absence of MMP13.
We excluded that the lack of effects was due to compensatory
transcriptional changes of other MMPs or their inhibitors
expressed in the MMTV-PyMT tumors.
MMP13 has a broad substrate profile that includes several
fibrillar collagens, tenascin, fibronectin and proteoglycans
[11,34,35]. Mmp13 mRNA was found in carcinoma-associated
fibroblasts located in the central areas of the MMTV-PyMT
tumors, where tumor dedifferentiation and invasion is prominent.
In these areas, we found increased thin collagen fibers relative to
total collagen in MMTV-PyMT;Mmp132/2 compared to MMTV-
PyMT;Mmp13+/+ tumors, indicating that MMP13 influences
collagen fiber formation and/or metabolism of fibrillar collagen
in the MMTV-PyMT stroma. Mice lacking Mmp13 display no
major phenotypic abnormalities [21,36], but a significant
contribution of MMP13 in collagen metabolism has been reported
during bone development [21,36], skeletal regeneration [37] and
in atherosclerotic plaques [38].
We found that most of the Mmp13 mRNA expressing cells in the
MMTV-PyMT tumors are carcinoma-associated myofibroblasts.
The myofibroblast is an abundant cell type in the MMTV-PyMT
tumors (this study) as it is in invasive human breast cancers [39].
There are several reports suggesting that carcinoma-associated
myofibroblasts promote cancer progression [40–42]. In addition,
proteins expressed by myofibroblasts, such as PAI-1 and uPA, are
associated with poor prognosis for breast cancer patients [43,44].
Figure 6. Absence of MMP13 is not compensated for by changes in mRNA expression of other MMPs or TIMPs. Expression of Mmp and
Timp mRNAs, relative to 18S ribosomal RNA, in MMTV-PyMT;Mmp13+/+ (white boxes, n=6) and MMTV-PyMT;Mmp132/2 (gray boxes, n= 6) tumors. In
the box and whiskers plot, all values are normalized to the median value of the MMTV-PyMT;Mmp13+/+ group. Horizontal lines indicate the median
and the boxes include the 25th and 75th percentiles. The lines outside the boxes correspond to highest or lowest values observed when these did not
fall within the quartiles, and circles (white or gray) correspond to outlier values.
doi:10.1371/journal.pone.0002959.g006
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It is unknown what induces Mmp13 in the breast carcinoma-
associated myofibroblasts, but the restricted expression of Mmp13
in dense fibrous stromal septae within the central parts of the
invasive MMTV-PyMT tumors suggests a locally expressed
tumor-cell derived factor. In vitro studies have shown that IL-1a,
IL-1b, and transforming growth factor-b1, in particular, can
induce Mmp13 mRNA expression in fibroblasts [45]. Interestingly,
TGFb signaling through fibroblast-expressed TGFb receptor type
II has a considerable impact on tumor growth [46]. Mmp13
mRNA expressing myofibroblasts are often found in the tumor
core close to areas with necrosis suggesting that MMP13 may be
upregulated in response to hypoxia for stimulation of angiogenesis.
Figure 7. Absence of MMP13 influences fibrillar collagen in the MMTV-PyMT tumor stroma. (A) Tissue sections from MMTV-PyMT;Mmp13+/+
(a-d) and MMTV-PyMT;Mmp132/2 (e–h) tumors stained with haematoxylin and eosin (a,e) or picrosirius red (b,f), the latter illuminated with linearly
polarized light. Color threshold images of total collagen (c,g) and thin collagen fibers (d,h) of the images in b and f, respectively. (B) Box plots of total
collagen (left), thin collagen fibers (middle) and the ratio between thin collagen fibers and total collagen (right, *p,0.01, t-test) measured in MMTV-
PyMT;Mmp13+/+ (gray boxes, n=26) and MMTV-PyMT;Mmp132/2 (white boxes, n=21) tumors as shown in the A panel.
doi:10.1371/journal.pone.0002959.g007
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Indeed, Mmp13 mRNA is induced by hypoxia in various cell lines
[47–49] including fibroblasts [49], and vasculature of ossification
sites and migration of endothelial cells into cartilage is impaired in
Mmp132/2 mice [50]. However, our measurements of vascular
diameter, length and volumes in MMTV-PyMT tumors did not
reveal any effect of MMP13 on tumor vascularization.
It has been reported that Mmp8 and Mmp9 mRNAs are
upregulated during bone development in the ossification sites in
Mmp132/2 mice [36] and that Mmp8 mRNA is upregulated
during skin wound healing in Mmp132/2 mice [51]. We tested
whether the mRNA expression levels of several MMPs were
changed in MMTV-PyMT;Mmp132/2 tumors, but found no
significant changes. We found that tumor progression in the
MMTV-PyMT model was associated with strong upregulation of
the Mmp13 mRNA level as compared to the normal mammary
gland. Preliminary results suggest that Mmp10 and Mmp12 mRNA
also are upregulated, while Mmp2, -3, -8, -9, -11, and -14 are not
(TXP, CP, DE, unpublished data). This suggests that the three
MMPs are upregulated by a common mechanism and potentially
implicates MMP10 and MMP12 in tumorigenesis in the MMTV-
PyMT model even though MMP10 and MMP12 mRNAs were not
significantly upregulated in the MMTV-PyMT;Mmp132/2 tumors
compared to MMTV-PyMT wild type tumors. However, we
cannot exclude that differences exist at the level of enzyme activity
or that other classes of proteolytic enzymes compensate for the
absence of MMP13. The expression of Mmp13 mRNA is strongly
restricted compared to the expression of Mmp2 and Mmp14
mRNAs that are expressed in a broader group of (myo)fibroblasts.
We have previously reported that mRNAs for several MMPs,
including Mmp2, Mmp3, Mmp11 and Mmp14 are expressed in the
MMTV-PyMT tumor stroma [18]. Of these MMPs, MMP2 and
MMP14 may have substrates in common with MMP13, for
example, both are also collagenases in vivo [3]. Therefore MMP2,
MMP14 or the activity of other MMPs may compensate for the
lack of MMP13 in the MMTV-PyMT;Mmp132/2 tumors.
It is possible that MMP13 plays both promoting and inhibiting
roles during cancer progression, resulting in a neutral net effect in
its absence in the MMTV-PyMT model. Tumor promoting and
inhibiting functions have been found for MMP9 in the human
papilloma virus (HPV) 16 skin cancer model where the absence of
Mmp9 reduced the number of tumors, but the tumors that formed
were more aggressive [4]. A tumor protective role of a number of
matrix degrading proteases, including MMP8 and MMP12, has
been described [52]. These studies emphasize the need for better
understanding the role not only of the individual proteases but also
of their separate activities in cancer progression.
Breast cancer progression in humans may have a larger
contribution from the stromal environment than murine tumors,
since human tissue have a more fibroblast-rich stroma than
murine [6]. Nevertheless, the MMTV-PyMT breast cancer model
shares many histological and molecular characteristics with human
luminal breast cancer [14,15,17], but it differs from human ductal
carcinoma in one interesting aspect: the myoepithelial cells, which
represent a cellular barrier for tumor cells and are an important
source for basement membrane, are partly lost early during
MMTV-PyMT oncogene-induced tumor progression [15]. The
absence of an intact myoepithelial barrier may lead to pre-invasive
precursor lesions different from human DCIS and render MMP13
a dispensable proteinase in the critical transition phase from non-
invasive to invasive carcinoma. Thus, despite the presence of a
heterogeneous stromal environment and the appearance of a
considerable myofibroblast population in the MMTV-PyMT
tumors, myofibroblasts may play a minor role for the overall
progression of the MMTV-PyMT tumor compared to human
breast cancer. Therefore, models in which transition from DCIS to
invasive carcinoma occurs similar to in human tumors are needed
to definitely rule out a role of MMP13 in breast cancer.
In conclusion, we found that the absence of MMP13 in the
MMTV-PyMT mice did not result in any differences in tumor
progression to invasive and metastatic breast carcinoma. Carci-
noma-associated fibroblasts have been shown to facilitate tumor
progression through stimulation of angiogenesis, growth factor
secretion and invasion [53–55]. However, there are no good
markers allowing systematic sub-classification of these cells. Thus,
even though MMP13 itself apparently is dispensable for tumor
progression in the MMTV-PyMT model, its restricted expression
in myofibroblasts in invasive regions suggests that it marks a
subpopulation of carcinoma-associated fibroblasts that are in-
volved in the transition to invasive carcinoma.
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